1. A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. (16th March 2015) Authors: Nechushtan, Hovav; Hamamreh, Yousef; Nidal, Salim; Gotfried, Maya; Baron, Amichai; Shalev, Yossi Israeli; Nisman, Benjjamin; Peretz, Tamar; Peylan-Ramu, Nili Journal: Oncologist Issue: Volume 20:Number 4(2015) Page Start: 366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non‐Small Cell Lung Cancer. (16th March 2015) Authors: Nechushtan, Hovav; Hamamreh, Yousef; Nidal, Salim; Gotfried, Maya; Baron, Amichai; Shalev, Yossi Israeli; Nisman, Benjjamin; Peretz, Tamar; Peylan‐Ramu, Nili Journal: Oncologist Issue: Volume 20:Number 4(2015) Page Start: 366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. Issue 3 (19th January 2020) Authors: Shaul, Merav E.; Eyal, Ophir; Guglietta, Silvia; Aloni, Pazzit; Zlotnik, Asaf; Forkosh, Ester; Levy, Liran; Weber, Lukas M.; Levin, Yonathan; Pomerantz, Alon; Nechushtan, Hovav; Eruslanov, Evgeniy; Singhal, Sunil; Robinson, Mark D.; Krieg, Carsten; Fridlender, Zvi G. Journal: FASEB journal Issue: Volume 34:Issue 3(2020) Page Start: 4204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. Issue 1 (24th September 2020) Authors: Goldstein, Iris M; Roisman, Laila C; Keren-Rosenberg, Shoshana; Dudnik, Julia; Nechushtan, Hovav; Shelef, Ilan; Fuchs, Vered; Kian, Waleed; Peled, Nir Journal: Neuro-oncology advances Issue: Volume 2:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy. (15th September 2015) Authors: Rachmin, Inbal; Amsalem, Eden; Golomb, Eliahu; Beeri, Ronen; Gilon, Dan; Fang, Pengfei; Nechushtan, Hovav; Kay, Gillian; Guo, Min; Yiqing, Peter Li; Foo, Roger S.-Y.; Fisher, David E.; Razin, Ehud; Tshori, Sagi Journal: International journal of cardiology Issue: Volume 195(2015) Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization. (November 2019) Authors: Kadouri, Luna; Rottenberg, Yakir; Zick, Aviad; Hamburger, Tamar; Lipson, Doron; Peretz, Tamar; Nechushtan, Hovav Journal: Lung cancer Issue: Volume 137(2019) Page Start: 48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. (August 2016) Authors: Dudnik, Elizabeth; Yust-Katz, Shlomit; Nechushtan, Hovav; Goldstein, Daniel A.; Zer, Alona; Flex, Dov; Siegal, Tali; Peled, Nir Journal: Lung cancer Issue: Volume 98(2016) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. (August 2016) Authors: Dudnik, Elizabeth; Yust-Katz, Shlomit; Nechushtan, Hovav; Goldstein, Daniel A.; Zer, Alona; Flex, Dov; Siegal, Tali; Peled, Nir Journal: Lung cancer Issue: Volume 98(2016) Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Issue 1 (27th December 2021) Authors: Peled, Nir; Kian, Waleed; Inbar, Edna; Goldstein, Iris M; Zemel, Melanie; Rotem, Ofer; Rozenblum, Anna B; Nechushtan, Hovav; Dudnik, Elizabeth; Levin, Daniel; Zer, Alona; Keren-Rosenberg, Shoshana; Yust-Katz, Shlomit; Fuchs, Vered; Remilah, Areen A; Shelef, Ilan; Roisman, Laila C Journal: Neuro-oncology advances Issue: Volume 4:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. (1st January 2021) Authors: Dudnik, Elizabeth; Moskovitz, Mor; Rottenberg, Yakir; Lobachov, Anastasiya; Mandelboim, Rinat; Shochat, Tzippy; Urban, Damien; Wollner, Mira; Nechushtan, Hovav; Rotem, Ofer; Zer, Alona; Daher, Sameh; Bar, Jair Journal: Oncoimmunology Issue: Volume 10:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗